Winston Kung - 21 Sep 2022 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Director
Signature
/s/ Maria Dobek, Attorney-in-Fact
Issuer symbol
JANX
Transactions as of
21 Sep 2022
Net transactions value
$0
Form type
4
Filing time
22 Sep 2022, 18:00:47 UTC
Previous filing
21 Apr 2022
Next filing
30 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JANX Stock Option (right to buy) Award $0 +30,000 $0.000000 30,000 21 Sep 2022 Common Stock 30,000 $13.54 Direct F1
transaction JANX Stock Option (right to buy) Award $0 +9,375 $0.000000 9,375 21 Sep 2022 Common Stock 9,375 $13.54 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option vest in equal monthly installments over a three year period following September 21, 2022 (the "Grant Date") such that the option is fully vested on the third anniversary of the Grant Date.
F2 The shares subject to the option vest in equal monthly installments over a one year period following September 21, 2022 (the "Grant Date") such that the option is fully vested on the first anniversary of the Grant Date.